SCHEMBL6030616

SCHEMBL6030616

CCCCCCC(CC)CCCCCOC(=O)Nc1sccc1C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.44
ABCC1 P33527 1/20 0.44
PRSS1 P07477 1/20 0.44
PRSS2 P07478 1/20 0.44
PRSS3 P35030 1/20 0.44
CSNK2A2 P19784 3/20 0.43
CSNK2A1 P68400 3/20 0.43
PTPN2 P17706 1/20 0.42
PTPRB P23467 1/20 0.42
PTPN6 P29350 1/20 0.42
SMN1; SMN2 Q16637 5/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
LMNA P02545 2/20 0.40
HPGD P15428 1/20 0.39
EPHX1 P07099 1/20 0.39
ALDH1A1 P00352 2/20 0.39
TSHR P16473 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6031356 1.00 L3MBTL1 (0.44) L3MBTL1ABCC1PRSS1PRSS2PRSS3
SCHEMBL6031467 0.86 PRSS1 (0.42) L3MBTL1PRSS1PRSS2PRSS3CSNK2A2
SCHEMBL6029664 0.86 PRSS1 (0.42) L3MBTL1PRSS1PRSS2PRSS3CSNK2A2
SCHEMBL6031446 0.76 ALDH1A1 (0.52) L3MBTL1ABCC1PTPN2PTPRBPTPN6
SCHEMBL6030322 0.76 ALDH1A1 (0.52) L3MBTL1ABCC1PTPN2PTPRBPTPN6
SCHEMBL10470287 0.75 ABCC1 (0.58) ABCC1PTPN2PTPRBPTPN6SMN1; SMN2
SCHEMBL13139581 0.74 PTK2 (0.57) L3MBTL1SMN1; SMN2NPC1RAB9AHPGD
SCHEMBL6031361 0.73 CSNK2A2 (0.41) L3MBTL1ABCC1CSNK2A2CSNK2A1SMN1; SMN2
SCHEMBL11522339 0.73 EPHX1 (0.51) L3MBTL1CSNK2A2CSNK2A1SMN1; SMN2NPC1
SCHEMBL6030754 0.72 CSNK2A2 (0.48) L3MBTL1CSNK2A2CSNK2A1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7064122-B2 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2006-06-20 US disclosed
EP-1467978-A4 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARM INC (US) 2005-11-02 EP disclosed
EP-1467978-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI Pharmaceuticals, Inc. (US) 2004-10-20 EP disclosed
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2003-10-16 US disclosed
WO-2003053944-A1 PANCREATIC LIPASE INHIBITOR COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARMACEUTICALS, INC. (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195199-A1 Pancreatic lipase inhibitor compounds, their synthesis and use PNLIP, LIPC, CEL L3MBTL1 1266/4885ABCC1 1228/4885PRSS1 363/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.